Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Alexandra Bähre"'
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
Bladder cancer is a frequent malignancy and has a clinical need for new therapeutic approaches. Antibody and protein technologies came a long way in recent years and new engineering approaches were applied to generate innovative therapeutic entities
Externí odkaz:
https://doaj.org/article/2baf03aa60ca4d78ac97ae835d7c5f92
Publikováno v:
Frontiers in Oncology
Frontiers in Oncology, Vol 11 (2021)
Frontiers in Oncology, Vol 11 (2021)
Bladder cancer is a frequent malignancy and has a clinical need for new therapeutic approaches. Antibody and protein technologies came a long way in recent years and new engineering approaches were applied to generate innovative therapeutic entities
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::215cd7b0f15f2efec3d816a5154d0ca9
https://pubmed.ncbi.nlm.nih.gov/34123841
https://pubmed.ncbi.nlm.nih.gov/34123841
Publikováno v:
5.1 Airway Pharmacology and Treatment.
Monoclonal antibodies (mAb) have transformed medicine but their ∼160 kD molecular weight and fragility make inhalation technically difficult, limiting utility in lung disease. Lipocalin-1 (LCN1) is a 17kD endogenous non-glycosylated, nest-like prot
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::13df19674bcd6e13f6ac7b69fde6dc2e
https://doi.org/10.1183/13993003.congress-2015.oa3256
https://doi.org/10.1183/13993003.congress-2015.oa3256
Autor:
Hartmut Goldschmidt, Sergey Kipriyanov, Thomas Moehler, Holger J. Schäfer, Marike J. J. G. Stassar, Alexandra Bähre, Björn Cochlovius, Jana Schlenzka, Axel Benner, Melvyn Little, Martin Kornacker
Publikováno v:
Anti-Cancer Drugs. 15:915-919
Combining different treatment strategies offers the possibility of improving treatment results for cancer patients. The aim of our study was therefore to investigate the combination of treatment of established s.c. human B non-Hodgkin's lymphoma in s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9328d2700314842d597f2262f0bb5a54
https://doi.org/10.1097/00001813-200410000-00013
https://doi.org/10.1097/00001813-200410000-00013
Autor:
Björn Cochlovius, Stefan Knackmuss, Sergey Kipriyanov, Melvyn Little, Alexandra Bähre, Fabrice Le Gall, Gerhard Moldenhauer, Holger J. Schäfer
Publikováno v:
Journal of immunology (Baltimore, Md. : 1950). 169(1)
To target NK cells against non-Hodgkin’s lymphoma, we constructed a bispecific diabody (BsDb) with reactivity against both human CD19 and FcγRIII (CD16). Bacterially produced CD19 × CD16 BsDb specifically interacted with both CD19+ and CD16+ cell
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5d4f2feb4f4f2bceca778c6773a0df74
https://pubmed.ncbi.nlm.nih.gov/12077238
https://pubmed.ncbi.nlm.nih.gov/12077238
Publikováno v:
Immunology letters. 80(2)
ScOKT3-gammaDeltaIgM VAEVD is a recombinant chimeric anti-CD3 antibody variant consisting of the light and heavy variable binding domains of the OKT3 monoclonal antibody and the CH3 and CH4 domains of a human IgM mutation linked by a human IgG3 hinge
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9fbfe3ce96a7f6fad39d156efa0e524e
https://pubmed.ncbi.nlm.nih.gov/11750044
https://pubmed.ncbi.nlm.nih.gov/11750044